Rocket Pharmaceuticals Reports Key Data, Development Milestones Demonstrated During Danon Disease Investor Webinar For Its Pivotal Phase 2 Study In Participants Treated Under Modified Protocol

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, highlighted key findings and development milestones presented during its October 6 Danon disease investor webinar. The update outlined a defined path to completing the FDA-aligned pivotal Phase 2 trial, highlighted sustained biological activity in longer-term Phase 1 follow-up and reported encouraging initial safety observations in the first three patients treated under the modified protocol.